The Innovations in Type-1 Diabetes (iT1D) Goal-Directed Program is currently conducting six clinical trials with a team of 13 principal investigators and co-investigators from three provinces – Ontario, Quebec and Manitoba – investigating innovative therapies to treat and improve the lives of those living with T1D. The Program co-leads are Dr. Bruce Perkins (University of Toronto) and Dr. Peter Senior (University of Alberta). These studies include patient-oriented research studies evaluating new therapies in diabetic neuropathy, artificial pancreas, adjunct drugs and immunotherapies.
This year the iT1D Research Program was able to participate in a ‘first of its kind’ CIHR SPOR Innovative Clinical Trial (iCT) multi-year operating grant competition, with funding matched by the JDRF. This competition not only focussed on designing innovative clinical trials to reduce the burden of continual self-management of persons with T1D, but also had a large emphasis on patient engagement in designing these trials with outcomes that will be accessible, manageable and directly applicable to their direct health concerns. Of the eight applications that went forward in this competition, three were funded to a maximum of $3,000,000 over 4 years.
Diabetes Action Canada co-investigators Dr. Gillian Booth and Dr. Remi Rhabasa-Lhoret were among the awardees, as well as Dr. Farid Mahmud from the Can-SOLVE CKD SPOR Network. Below is a brief description of each study.
More information on these studies can be found here: Clinical Trials
The value of patient and public involvement in the design of research questions is recognized increasingly across the globe. Engaging patient partners in setting research priorities increases the generation and uptake of new evidence that is meaningful and relevant to the community, while reduces wasted resources. The iT1D program works with people living with T1D at many levels to direct project planning towards outcomes that address the health and social concerns to the T1D community. We have learned a tremendous amount from this experience, and have identified a gap in connecting individuals with T1D, healthcare practitioners and researchers, who are all interested in connecting with their peers and each other. To bridge this gap we are creating a T1D Registry to first act as a patient empowerment and engagement community that also facilitates clinical research in Canada. To join this virtual community an eConsent platform and digital infrastructure will be created to allow people living with T1D to register and have a safe environment to have their voices heard, their stories told, their reported data be used to benefit the T1D Community, and their data be used to help with scientific advances in T1D. To help us develop this tool so it is both useful and inspiring to individuals living with T1D we are engaging our Diabetes Action Canada Patient Partners and the T1D ThinkTank, to learn from patient narratives and understand individual and group experiences in healthcare and quality of life. In November 2018, we conducted a full day Insight Session below is a living graphic from our most recent collaborative Insight Session.
Summary graphic for the Diabetes Action Canada and The T1D ThinkTank Collaborative Insight Session. Graphic created by Erica Bota from Think Link
Report from Collaborative Insight Session can be found here
© 2019 Diabetes Action Canada – SPOR Network
project by i+.